TABLE 4.
Adverse events of special interest in the dose expansion cohort (part 2)
| Preferred term | N = 17 | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Any grade | |
| Patients with ≥1 ocular TEAE | 3 (17.6) | 3 (17.6) | 0 | 6 (35.3) |
| Conjunctivitis | 1 (5.9) | 2 (11.8) | 0 | 3 (17.6) |
| Conjunctivitis allergic | 0 | 1 (5.9) | 0 | 1 (5.9) |
| Scleritis | 0 | 1 (5.9) | 0 | 1 (5.9) |
| Hordeolum | 1 (5.9) | 0 | 0 | 1 (5.9) |
| Vision blurred | 1 (5.9) | 0 | 0 | 1 (5.9) |
| Patients with ≥1 peripheral neuropathy TEAE | 3 (17.6) | 0 | 0 | 3 (17.6) |
| Peripheral sensory neuropathy | 3 (17.6) | 0 | 0 | 3 (17.6) |
| Patients with ≥1 bleeding TEAE | 8 (47.1) | 2 (11.8) | 3 (17.6) | 13 (76.5) |
| Epistaxis | 8 (47.1) | 0 | 0 | 8 (47.1) |
| Lower gastrointestinal hemorrhage | 2 (11.8) | 0 | 1 (5.9) | 3 (17.6) |
| Genital hemorrhage | 1 (5.9) | 1 (5.9) | 0 | 2 (11.8) |
| Tumor hemorrhage | 0 | 0 | 2 (11.8) | 2 (11.8) |
| Anal hemorrhage | 0 | 1 (5.9) | 0 | 1 (5.9) |
| Hematochezia | 1 (5.9) | 0 | 0 | 1 (5.9) |
| Vaginal hemorrhage | 1 (5.9) | 0 | 0 | 1 (5.9) |
Abbreviation: TEAE, treatment‐emergent adverse event.